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Microbial natural products exhibit immense structural diversity and complexity and have
captured the attention of researchers for several decades. They have been explored
for a wide spectrum of applications, most noteworthy being their prominent role in
medicine, and their versatility expands to application as drugs for many diseases.
Accessing unexplored environments harboring unique microorganisms is expected
to yield novel bioactive metabolites with distinguishing functionalities, which can be
supplied to the starved pharmaceutical market. For this purpose the oceans have
turned out to be an attractive and productive field. Owing to the enormous biodiversity
of marine microorganisms, as well as the growing evidence that many metabolites
previously isolated from marine invertebrates and algae are actually produced by their
associated bacteria, the interest in marine microorganisms has intensified. Since the
majority of the microorganisms are uncultured, metagenomic tools are required to exploit
the untapped biochemistry. However, after years of employing metagenomics for marine
drug discovery, new drugs are vastly under-represented. While a plethora of natural
product biosynthetic genes and clusters are reported, only a minor number of potential
therapeutic compounds have resulted through functional metagenomic screening. This
review explores specific obstacles that have led to the low success rate. In addition
to the typical problems encountered with traditional functional metagenomic-based
screens for novel biocatalysts, there are enormous limitations which are particular to
drug-like metabolites. We also present how targeted and function-guided strategies,
employing modern, and multi-disciplinary approaches have yielded some of the most
exciting discoveries attributed to uncultured marine bacteria. These discoveries set the
stage for progressing the production of drug candidates from uncultured bacteria for
pre-clinical and clinical development.
Keywords: uncultured microbes, metagenomics, symbionts, marine natural products, drug discovery, functional
screening
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Marine Microorganisms as a Novel
Source of Natural Products
Natural products remain a major resource for drug production
today and during the past 30 years, 70% of antimicrobials and
60% of chemotherapeutics have been developed or analogously
synthesized from them (Pomponi, 2001; Grüschow et al., 2011).
Traditionally, terrestrial sources have provided the bulk of natural
products for drugmolecules. However, participation by the major
pharmaceutical companies declined in the mid-nineties, largely
owing to the high rediscovery rate and decreased number of
novel compound identiﬁcations (Molinski et al., 2009). In the
meantime infectious diseases and multiple drug resistant strains
have bloomed, urging scientists to mine for novel drugs in non-
terrestrial and unexplored environments. A chemoinformatics
study showed that 71% of the marine natural products were
not represented in terrestrial natural products, and that 53%
have been found only once (Montaser and Luesch, 2011).
Complementary studies investigating the distribution of natural
products in chemical space has shown clearly that marine natural
products have the broadest distribution, covering many drug-
relevant areas (Tao et al., 2015). As such, the focus has recently
shifted to marine natural product bioprospecting, which has
delivered remarkably high hit rates (Gerwick and Moore, 2012;
Blunt et al., 2015).
The ocean harbors a number of ecological niches and has
proven to be home to more microorganisms than any other
environment. Considering that 70% of our planet’s surface is
covered by the oceans, it is not surprising that certain marine
ecosystems harbor much higher biological and chemical diversity
than what is found terrestrially. Furthermore, the sedentary
lifestyle of many of the organisms necessitates a chemical means
of defense, and as such natural products are produced as chemical
weapons which have evolved into highly eﬀective inhibitors
(Spainhour, 2005). Since the released compounds become rapidly
diluted, marine natural products tend to be highly potent in order
to be eﬀective (Haefner, 2003). The rich biodiversity contained
within the oceans (15 animal phyla exclusive to the oceans) makes
them a unique and rich drug discovery reservoir (Leal et al.,
2012).
Marine natural product discovery was initially focused on
the easily accessible macro-organisms (such as algae, soft corals,
and sponges) from which a range of bioactive compounds
have been described (Bergmann and Feeney, 1951; McGivern,
2007; Hu et al., 2011; Leal et al., 2012). However, eﬀorts
have gradually turned to the smaller forms of life such as
bacteria and fungi (Gerwick and Moore, 2012) which constitute
a large portion of the marine biomass (Sogin et al., 2006).
Considering the enormous number of microbes, their vast
metabolic diversity and the rate of mutations during the past
3.5 billion years, it is expected that there are high levels of
genetic and phenotypic variation in marine environments (Sogin
et al., 2006). Furthermore, marine microorganisms live in a
biologically competitive environment with unique, harsh, and
ﬂuctuating conditions. They encounter enormous physical and
chemical variability including low temperature, high pressure,
oligotrophy, high salinity and other competitive environments,
and are especially rich in chlorine and bromine elements.
Global scale analyses of bacterial diversity identify environment
salinity and temperature as the major determinants of microbial
community composition, resulting in distinct marine microbiota
being selected (Lozupone and Knight, 2007). Bioﬁlm formation
is a crucial aspect where cell densities are typically 100–1000
fold higher in a bioﬁlm assemblage than in the surrounding
water column (Wahl et al., 2012). Furthermore, the increased
competition amongst organisms is thought to be the source
of higher production levels of secondary metabolites (Teasdale
et al., 2009). In contrast to typical terrestrial environments,
marine environments have a very high bacterial diversity at
the higher taxonomic levels and a global biogeographical
study has shown that there is no more than 12% taxon
overlap between bacterial assemblages within and between
habitat types (Nemergut et al., 2011). As a result marine
microorganisms represent a unique source of genetic information
and biosynthetic capacity which translates to huge chemical
diversity.
Marine Microbial Natural Products
Marine microorganisms produce a vast variety of secondary
metabolites which could be used to supply the starved
pharmaceutical market. Microbial natural products have notable
potent therapeutic activities, and also often possess the desirable
pharmacokinetic properties required for clinical development
(Farnet and Zazopoulos, 2005). More than half of the known
natural products with anti-microbial, anti-tumor (Bewley and
Faulkner, 1998; Feling et al., 2003; Taori et al., 2008; Rath
et al., 2011) or anti-viral activity are of bacterial origin (Berdy,
2005). Additional categories include anti-parasitic (Kirst et al.,
2002; Abdel-Mageed et al., 2010), anti-nematodal (Donia and
Hamann, 2003), anti-inﬂammation (Strangman, 2007), and
neurological (Sudek et al., 2007). Pharmaceutically relevant
natural products belong to diﬀerent chemical classes that diﬀer
not only in structure, but also in the mechanisms by which
they are synthesized. The molecular classes which become
pharmaceuticals tend to be alkaloids, terpenoids, polyketides and
small peptides, and a wide range of bioactive properties are
observed within each class (Graça et al., 2013). Furthermore,
the elucidation of novel hybrid compounds is providing deeper
insights into fascinating enzyme assemblies and mechanisms
behind the diversity in structure and biological functions
observed in these compounds. Some marine derived microbial
examples can be found in the following references: alkaloids
(Charan et al., 2004; Abdelmohsen et al., 2012); terpenoids
(Kuzuyama and Seto, 2003; Cho et al., 2006; Strangman, 2007;
Solanki et al., 2008); polyketides (Olano et al., 2009; Harunari
et al., 2014), peptides (Pettit et al., 2009; Chopra et al., 2014);
and hybrids (Hardt et al., 2000; Feling et al., 2003; Oh et al., 2007;
Blunt et al., 2015).
An additional attraction of microbially derived natural
products is that they oﬀer an answer to the supply problem,
a major bottleneck in the drug discovery pipeline. The
progression of many marine natural products with promising
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pharmaceutical relevance into clinical phases are halted since
the clinical trial stage requires a considerable amount of
drug mass; usually kilogram amounts (Tsukimoto et al.,
2011). Most pharmaceutically interesting compounds are found
in minute amounts, therefore bioprospecting cannot rely
on wild-harvesting as it could lead to the extinction of
marine species. More economically feasible, environmentally
friendly, and sustainable sources of lead compounds are
required. Microbial-based production of lead compounds
therefore oﬀers a sustainable solution through the use of
culturable marine microorganisms (microbial fermentation).
Marine bacteria can respond positively during scaling up
processes, and can incorporate sustainable chemical processes
for faster establishment of a pilot plant for production (Abd
Elrazak et al., 2013). The current industrial process for the
production of Yondelis, for example, involves the fermentation
of Pseudomonas ﬂuorescens for the production of the starting
material cyanosafracin B, followed by semi-synthesis to generate
the ﬁnal drug (Cuevas et al., 2000). Furthermore, strain
intensiﬁcation and elicitation to improve expression are possible
through metabolic engineering, as well as the unlocking of
untapped cryptic biosynthetic pathways through heterologous
host expression (Li and Neubauer, 2014).
Marine Metagenomics
There is remarkable potential harbored within microorganisms
to produce diverse drug-like small molecules for a wide range
of applications. The impact and possible success of a single new
discovery distinguishes natural products from all other sources
of chemical diversity (Farnet and Zazopoulos, 2005). However,
traditional culture-based approaches used to identify microbial
metabolites likely miss the vast majority of bacterial natural
products. Only about 1% of bacteria are cultured in vitro and of
the approximately 61 bacterial phyla known, 31 lack cultivable
representatives (Vartoukian et al., 2010). Seawater bacteria have
a 10-fold lower representation of cultured isolates compared
to other environments (Amann et al., 1995). Therefore, if the
natural products discovered from cultured marine bacteria are
an indication of the diversity available, culture-independent
approaches are expected tomore successfully access the untapped
reservoir of chemical diversity and contribute many more novel
marine-derived discoveries.
The study of DNA obtained directly from an environmental
sample (metagenomics) accesses the collective genomes and
bioactive potential of bacterial consortia (Handelsman, 2004).
Metagenomics therefore provides a means of exploring novel
metabolites from bacteria that are known to be present in
marine environments but which remain recalcitrant to culturing
(Banik and Brady, 2010). Moreover, metagenomics is particularly
attractive for natural product discovery because the genetic
information encoding the activities of interest are generally
clustered on bacterial genomes, making it possible to clone an
entire pathway on an individual or at least a small number
of overlapping library clones (Handelsman et al., 1998; Banik
and Brady, 2010). Therefore, high throughput metagenomic
screening approaches, using both sequence-based and function-
based screening, can be employed, in theory, to de-replicate
known pathways and compounds and reduce the high degree
of redundancy obtained through traditional culture based
approaches. Metagenomic screening approaches cover a large
range of techniques and are subject to the speciﬁcations of the
target compound. The particular focus of this review is to evaluate
the impact of function-guided strategies as a tool in marine
natural product discovery. Speciﬁcally, we compare two diﬀerent
functional approaches and their contributions to unlocking the
natural product potential harbored inmarine microbial genomes.
Classic Functional Metagenomic
Screening
In natural product discovery, classical functional screening
involves the generation and subsequent screening of
metagenomic libraries for the direct detection of the metabolite’s
properties (e.g., antibacterial, antifungal, antitumor, antiviral
activity; Rocha-Martin et al., 2014; Figure 1). Using whole cells,
the culture supernatant or cell pellet extract, this screening
approach has been employed with some success. One of the
simplest strategies is to test for growth inhibition against a
test microbe in top agar overlay assays. This has led to the
characterization of a variety of new antibiotics from soil-derived
environments (Brady and Clardy, 2000, 2005; Curtois et al.,
2003), but no marine-derived studies have been reported, to our
knowledge. A more typical approach to functional screening is to
screen for a readily detectable phenotype which is representative
of the desired bioactive compound, either through the visual
detection of pigment production or the use of chromogenic
and ﬂuorogenic enzyme substrates which allow the detection
of speciﬁc catalytic functions encoded on individual clones
when incorporated into the growth medium (Ferrer et al.,
2009; Guazzaroni et al., 2015). The antibacterial pigments
violacein (Brady et al., 2001), indigo (Lim et al., 2005), and
turbomycins (Gillespie et al., 2002) have been isolated from soil
metagenomic libraries. Success with marine libraries; however,
has not been reported. A number of other function based
screens have yielded a range of diﬀerent bioactive compounds
or activities. Although these screens have not been employed in
marine library screening, they are worthy of mention because
we expect it is only a matter of time before they are reported.
An acylhomoserine lactone synthase promoter fused to a lacZ
reporter has been employed to identify AHL lactonases capable
of inhibiting Pseudomonas aeruginosa bioﬁlms (Schipper et al.,
2009). A phosphopantetheinyl transferase (PPTase)-targeting
functional screen has resulted in the eﬃcient recovery of natural
product gene clusters from metagenomic libraries (Owen
et al., 2012). Non-ribosomal peptide synthetase and polyketide
synthase (PKS) enzymes are activated by PPTases, therefore these
enzymes are frequently associated with secondary metabolite
gene clusters (Osbourn, 2010; Owen et al., 2012). There is a much
greater chance of detecting the expression of a single intact gene
than an entire biosynthetic operon, therefore focusing on only a
single gene target for the recovery of NRPS and PKS gene clusters
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FIGURE 1 | A comparison of two function-driven approaches to employ
metagenomics for the discovery and production of pharmaceutically
relevant marine natural products. Classic functional metagenomic
screening: metagenomic libraries are generated in a suitable host and activity
screened in a variety of ways, to detect clones expressing metabolites with
potential therapeutic properties. The active clones are sequenced to determine
the biosynthetic pathway. For certain classes of secondary metabolites,
sequence from overlapping clones may be required to compose the entire
pathway. The structure of the expressed metabolite is elucidated, following
chemical dereplication and characterization methods. If the metabolite is novel,
further functional characterization is conducted to evaluate its therapeutic
potential. Targeted metagenomic screening: these strategies are guided by
traditional chemistry and structure/function-based discoveries in which novel
natural products are first isolated and characterized directly from the marine
organism or environment. Guided by the chemical classification, a targeted
sequence-based analysis can be employed to identify whether the metabolite is
microbially encoded, and to subsequently describe the biosynthetic gene
cluster. This approach has been employed successfully (detailed in text) when
integrated with a number of technologies such as in situ hybridization, single-cell
sorting, and whole genome amplification (WGA). The sequence-based analysis
of the metagenomic DNA can include gene-targeting using degenerate PCR
amplification; or next generation sequencing of the clone library or of the
metagenomic DNA directly (shotgun). Where sufficient sequence information is
assembled, full genome information can be used to describe novel and
uncultured bacteria. The elucidation of the genetic clusters provides the
foundation for direct production of the pharmaceutical drug and new analogs
through metabolic engineering, and opens the possibility to produce the drugs
through heterologous expression.
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by association increases the chances of identifying “hits” (Owen
et al., 2012).
Function-driven screening strategies oﬀer signiﬁcant
advantages to sequence/homology based screening (Tuﬃn et al.,
2009; Kennedy et al., 2010; Suenaga, 2012). This is primarily
due to the fact that prior knowledge of the gene sequence for
the target activity of interest is not needed, and as a result it is
expected that functional screening increases the ‘novelty’ hit rate.
This increases the potential of identifying entirely new classes of
genes for both known and novel functions (Sharma and Vakhlu,
2014). Furthermore, the hits obtained represent an “insurance
policy”; guaranteed success of expression in the heterologous
host, enabling one to screen for particular properties and under
speciﬁed conditions, as well as facilitating downstream analyses.
The dearth of marine natural product discoveries through
functional metagenomics is puzzling considering the increased
research focus on marine microorganisms over the last decade
(Kennedy et al., 2010). We propose two major reasons for this,
(i) heterologous expression challenges and (ii) the sequence
technology boom.
Challenges Associated with Classic
Functional Metagenomics
Natural product discovery, using metagenomics, faces a number
of signiﬁcant challenges and limitations when employing classic
functional screening approaches (Kennedy et al., 2010; Li and
Neubauer, 2014; Reen et al., 2015). The most well-known
are those associated with heterologous gene expression. Gabor
et al. (2004) estimated using in silico analysis that only 40%
of enzymatic activities can be identiﬁed by random cloning
of environmental DNA in Escherichia coli. Many studies have
highlighted heterologous expression as an enormous challenge
limiting the robustness of metagenomics to fully access metabolic
potential (Ferrer et al., 2009; Uchiyama andMiyazaki, 2009; Reen
et al., 2015). In natural product discovery, these challenges are
augmented for a number of reasons.
(i) Unlike for other biotechnologically important enzymes
and activities typically screened in metagenomic studies, such
as the glycosyl hydrolases for example, the activities encoded
by particularly the PKS and NRPS pathways, require optimal
induction conditions of many genes for expression. The
enzymatic megacomplexes for dedicated synthesis of their
cognate products are encoded by massive gene clusters, some
composed of over 20 genes which are distributed between
multiple polycistronic transcriptional units (Gao et al., 2010;
Osbourn, 2010). Obviously there is a much lower chance
of expressing an entire biosynthetic pathway in any given
heterologous host than a single active enzyme. Secondary
metabolite pathways are regulated by pathway speciﬁc proteins
as well as global regulatory elements in response to changes
in nutrient conditions or environmental signals (Van Wezel
and McDowall, 2011). The extremely diverse marine speciﬁc
factors responsible for unique biochemistries are diﬃcult
to replicate in functional screening. For example, it is
well-understood that many secondary metabolite pathways
expressed in their natural environmental conditions remain
silent under laboratory conditions (Montaser and Luesch,
2011), and this is magniﬁed in heterologous systems. The
synergies associated with complex symbiotic and competitive
interactions cannot easily be incorporated in simple expression
systems.
(ii) Even if heterologous expression of a particular pathway is
successful, it may not necessarily produce the same compound.
Only one isomer may be active and not the other due
to the requirement of intermediate compound(s) from the
original host or environment (Taylor et al., 2007; Sagar et al.,
2010). Furthermore, the absence of a required post-translational
modiﬁcation process, the requirement of in trans genetic
elements or the fragmentation of previously clustered genes
would not allow functional detection (Kwan et al., 2012;
Nakabachi et al., 2013). The use and development of alternative
bacterial hosts, expression systems, andmulti-host shuttle vectors
is crucial to overcoming the limitations discussed. The ability to
screen using alternative transcriptional machinery and promoter
recognition capabilities should broaden the spectrum of gene
expression. Recently, in order to achieve good heterologous
expression of novel bioactive compounds, the development
of marine-derived hosts such as actinomycete, cyanobacteria,
and symbiotic fungi was undertaken to optimize heterologous
production (Rocha-Martin et al., 2014). The ability to replicate
in multiple hosts enables the screening to be conducted in
the background of diﬀerent regulatory and metabolic networks.
Furthermore, biosynthetic pathways have also been shown to
result in diﬀerent phenotypes when expressed in diﬀerent hosts
(Craig et al., 2010).
(iii) Owing to the large sizes of the biosynthetic pathways,
which routinely approach 100 kb, functional screening of
metagenomic libraries for the encoded activity is restricted by the
need for the entire cluster to be recovered on a single clone (Kim
et al., 2010). Libraries therefore need to be prepared in bacterial
artiﬁcial chromosomes (BACs), which can be maintained at
low copy number and can carry DNA inserts as large as
350 kb (Shizuya and Simon, 1992). However, it is a major
technical challenge to preserve the large size of the metagenomic
DNA while suﬃciently removing impurities that inhibit cloning.
In practice, metagenomic BAC libraries only manage 40 kb
insert sizes and rarely greater than 70–100 kb (Handelsman
et al., 1998; Kakirde et al., 2010). Furthermore, metagenomes
representing symbiotic communities associated with marine
invertebrates represent hundreds of individual genomes. To
adequately represent each one requires massive DNA libraries, in
the order of 106 clones, to be constructed and screened (Freeman
et al., 2012). Therefore, metagenome libraries generally vastly
underrepresent the true diversity, which has so far prohibited the
realization of a functional metagenomic approach (Fisch et al.,
2009).
(iv) Activities which are initially identiﬁed and associated with
a library clone extract are sometimes lost before the chemical
structure can be determined due to strong negative selection in
the heterologous system (Curtois et al., 2003).
(v) Microbial-derived compounds often have multiple
activities; for example anti-tumor (Abbas et al., 2013; Du et al.,
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2013), anti-inﬂammatory (Chandak et al., 2014), and anti-
protozoan (Abdel-Mageed et al., 2010) compounds also display
antibacterial activity which may be toxic to the heterologous host.
A large proportion of sought-after activities will therefore never
be represented in metagenomic libraries. This cannot necessarily
be overcome by the use of shuttle vectors because it is in the
initial library construction phase that the clones harboring toxic
activities will be lost. Ideally metagenomic libraries constructed
in shuttle vectors need to be transformed/transfected into the
multiple hosts; however, the levels of eﬃciency required are
diﬃcult to generate in non-E. coli hosts. Maintaining low copy
numbers may enable the host to survive the toxicity; however,
it is highly likely that the screening method will not be sensitive
enough to detect the active clone.
The Sequence Boom
To overcome some of the challenges associated with functional
screening, sequence/homology-based screening has been
employed in a number of diﬀerent ways. It is not the intention of
this review to compare function vs. sequence based metagenomic
methods; however, a brief review is presented to put into context
the need for continued attention to functional metagenomic
tools.
Metagenomic DNA or clone libraries can be screened using
degenerate PCR primers designed to conserved sequences
within biosynthetic gene clusters (Banik and Brady, 2010). The
clustering of biosynthetic genes on a contiguous region of
DNA makes homology-based screening attractive. The domain
architecture of PKSs and NRPSs in most cases mirrors the
structure of the assembled metabolite (Piel et al., 2004c).
Therefore, the use of degenerate primers is routinely and
successfully employed to ﬁrst detect conserved NRPS and
PKS motifs, followed by the recovery of the remainder of
the biosynthetic enzymes by association (Moﬃtt and Neilan,
2001; Dunlap et al., 2007; Bayer et al., 2013). Furthermore, the
identiﬁcation of relatives of known biosynthetic variants could
be a strategy to identify or synthesize new structural variants to
provide compounds with improved pharmacological properties
(Banik and Brady, 2010). However, in some cases up to 99%
of the genes detected through PCR screening can represent
dominant sequences which are already known and alternative
strategies are required to overcome the presence of similar
sequences (Piel et al., 2004c; Schirmer et al., 2005; Fieseler et al.,
2007; Kennedy et al., 2008; Hochmuth et al., 2010; Siegl and
Hentschel, 2010; Pimentel-Elardo et al., 2012; Della Sala et al.,
2013, 2014).
Exciting advancements in next generation DNA sequencing
and bioinformatics technologies now negates the need to prepare
and sequence clone-libraries. Shotgun metagenomic sequencing
has made it possible to rapidly identify large biosynthetic gene
clusters and subsequent predictions of their chemical structure
can be made (Caboche et al., 2008, 2010; Röttig et al., 2011;
Medema et al., 2012, 2014; Blin et al., 2013). While purely
in silico approaches are generally limited to the detection of one
or more well-characterized gene cluster classes (Cimermancic
et al., 2014), continued developments in bioinformatics pipelines
and other technologies are already improving access to diverse
and novel secondary metabolite genes and clusters, including
providing access to the “rare biosphere” (we refer readers to a
number of examples: Li et al., 2010; Sagar et al., 2010; Trindade-
Silva et al., 2012; Woodhouse et al., 2013; Cimermancic et al.,
2014). Furthermore, the deposition of more functionally curated
sequence data in publically available databases should improve
the ability to use purely bioinformatics based screening for the
identiﬁcation of novel gene clusters (Tuﬃn et al., 2009; Suenaga,
2012).
In silico approaches facilitate rapid dereplication of common
biosynthesis clusters and thus the prioritization of new chemical
scaﬀolds for experimental characterization. Although, targeted
induction in heterologous expression systems has delivered
some success from the marine environment (Long et al., 2005;
Schmidt et al., 2005; Hochmuth et al., 2010; Rath et al., 2011;
Bonet et al., 2015; Li et al., 2015), it is not easily going to
deliver compounds with the sought after properties required
by the pharmaceutical markets in a high throughput manner,
when taking a purely in silico discovery route. For example,
the swf cluster, a new mono-modular type I PKS/FAS (fatty
acid synthase) was identiﬁed through screening of the Plakortis
simplex sponge metagenome (Della Sala et al., 2013). The entire
pathway was expressed in E. coli; however, the production of an
associated metabolite was not detected.
Notwithstanding all the diﬃculties associated with
heterologous expression and the inability to conduct this in
a high throughput manner, novel sequence will not necessarily
result in the pharmaceutically required biological properties.
It is currently easier and cheaper to generate vast volumes of
gene and genome sequence information than it is to produce
the experimental characterizations, and the gap between these is
growing rapidly (Prakash and Taylor, 2012; Scholz et al., 2012;
Teeling and Glöckner, 2012; Reen et al., 2015).
Targeted Metagenomic Strategies in
Marine Discovery
From a pharmaceutical point of view, marine drug discovery
necessitates a focus on functionality. Irrespective of the approach
employed, obtaining biologically active and pure compounds
with the desired activity or properties is the end goal. The ability
to achieve this through function-driven screening strategies
is, in principle, the golden standard. Given the limitations
discussed above this will remain a major challenge. Relative
to other environmental biodiscovery eﬀorts, classical functional
metagenomic screening of marine sources has yet to contribute
signiﬁcantly to the pharmaceutical industry. However, signiﬁcant
improvements in the chemical and genetic sciences and the
integration of these technologies, has resulted in a number of
successes which are beginning to drive the development of
parallel technologies.
Instead of functionally screening a metagenome clone library,
a targeted approach which harnesses prior knowledge of marine
natural product diversity, chemistry, and biological activity is
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bridging the gap between the accumulation of microbial genetic
datasets and functional and ecological relevance (Figure 1). In
this section we highlight some of the recent discoveries that have
employed metagenomic strategies which were guided primarily
by initial structural and functional characteristics and associated
pharmaceutical interest.
Bryostatins
Bryostatin 1, a polyketide initially detected in 1968 in extracts
from the marine bryozoan Bugula neritina (Pettit, 1991), raised
interest due to its cytotoxic activity against multiple carcinomas,
with proteinase kinase C as its molecular target (Mayer et al.,
2010). Bryostatin 1 has been tested in over 80 clinical trials
for cancer and is also being assessed in Phase I trials as an
anti-Alzheimer’s drug. Although the in vivo activity was initially
detected directly from the bryozoan, it was for many years
suspected that the compound was produced by a bacterial
symbiont since a diﬀerence in the types of bryostatins found
in B. neritina correlated with genetically diﬀerent bacterial
symbionts (Davidson andHaygood, 1999). A particular symbiont
in the larvae of the bryozoan was identiﬁed and suspected
to be the producer, and was proposed as a novel gamma-
proteobacterium, ‘Candidatus Endobugula sertula.’ Attempts to
separate the bacterial cells from the host as a way to conﬁrm Ca
E. sertula as the producer of the bryostatin were inconclusive,
therefore a metagenomic approach was employed (Davidson
et al., 2001). Since, bryostatin is a type I polyketide, PKS-
based screening was conducted and led to the conﬁrmation that
the genes coding for type I PKS complex were derived from
the symbiotic population. Further query involving the growth
of B. neritina colonies after antibiotic treatments and in situ
hybridization experiments conﬁrmed that “E. sertula” was the
source of the bryostatins. A cosmid library was prepared from
B. neritina Mission Bay metagenomic DNA, and was screened
by hybridization (Hildebrand et al., 2004) using a β-ketoacyl
synthase probe identiﬁed previously (Davidson et al., 2001).
Several overlapping clones were sequenced revealing the 65 kb
bry gene cluster (Hildebrand et al., 2004). Probes spanning the bry
gene cluster were hybridized to ‘Candidatus E. sertula’-enriched
DNA to conﬁrm the symbiont as the origin of the gene cluster.
Further interrogation in two closely related “E. sertula” strains
from diﬀerent host species identiﬁed two diﬀerent gene cluster
arrangements (Sudek et al., 2007). In one strain the gene cluster
is contiguous, while in the other strain the PKS genes are split
from the accessory genes. Due to the diﬃculties in obtaining
suﬃcient supply of the bryostatins, their clinical application
occurred decades after their discovery. Since “E. sertula” remains
unculturable, heterologous expression of the bry gene cluster
could be considered for the production of bryostatins in large
enough quantities for pharmaceutical development.
ET-743 (Yondelis
R©
)
Anti-cancer activity in extract from the sea squirt Ecteinascidia
turbinata was identiﬁed in 1969; however, it was only in 1984
that the structure of one of the compounds, Ecteinascidin 743
(ET-743), was determined (Rinehart, 2000). ET-743 (Yondelis R© )
is now an approved anti-cancer agent (Bewley and Faulkner,
1998). Attempts to farm the sea squirt to provide suﬃcient
supply of the compound had limited success, and it is currently
generated in suitable quantities for clinical use by a lengthy
semi-synthetic process (Cuevas et al., 2000; Rath et al., 2011).
The similarity of ET-743 to three other bacterial derived natural
products (saframycin A, Streptomyces lavendulae; saframycin
Mx1, Myxococcus xanthus; safracin B, Pseudomonas ﬂuorescens;
Rath et al., 2011) suggested that ET-743 was produced by a
marine bacterial symbiont. Using metagenomic sequencing of
total DNA from the microbial consortium associated with the
tunicate resulted in the assembly of a 35 kb contig containing
25 genes encoding a NRPS biosynthetic pathway. Rigorous
sequence analysis of two large unlinked contigs suggested that
‘Candidatus Endoecteinascidia frumentensis’ was the producer
of the metabolite. Subsequent metaproteomic analysis conﬁrmed
expression of three key biosynthetic proteins. The complete
genome of ‘Candidatus Endoecteinascidia frumentensis’ was very
recently determined, showing an extremely reduced genome
(∼631 kb) and evidence of an endosymbiotic lifestyle (Schoﬁeld
et al., 2015). Having the pathway elucidated provides the
foundation for direct production of the drug and new analogs
through metabolic engineering (Rath et al., 2011).
Patellazoles
The Lissoclinum patella tunicate has garnered interest due to
it representing a rich source of potential bioactive drug leads
(Kwan et al., 2012; Schmidt et al., 2012). The patellazoles
were isolated directly from the tunicate in the late 1980s and
characterized as a new family of novel thiazole-containing
polyketide metabolites (Corley et al., 1988; Zabriskie et al., 1988).
In addition to their chemical novelty, they gained interest due
to their potent cytotoxic activity against human cell lines as well
as antifungal (Candida albicans) activity (Zabriskie et al., 1988).
The patellamides, also isolated from this tunicate had already
been shown to be produced by the cyanobacterial symbiont,
Prochloron didemni (Schmidt et al., 2005). Although, P. didemni
is the major symbiont, L. patella harbors a complex microbiome
(Donia et al., 2011), and therefore there stood the possibility
that the patellazoles were also produced by a symbiont. Due to
the multiple acetate units, patellazoles were hypothesized to be
produced by a type I PKS pathway, as well as a NRPS module for
the incorporation and cyclization of a cysteine unit to generate
the thiazole ring (Kwan et al., 2012). Based on this information
an exhaustive sequence based screening of a metagenome
clone library prepared from the tunic-cloaca habitats was
undertaken, but did not locate the biosynthetic pathway. PCR
ampliﬁcation revealed PKS genes from the trans-acyltransferase
family, consistent with patellazole biosynthesis, in the tiny zooids
but not in the bulk tunic. DNA extracted from the zooids
fraction was subjected to shotgun sequencing and the assembly
thereof resulted in a complete genome which contained a 86 kb
trans-AT PKS pathway. The predicted biosynthetic model of the
encoded pathway was consistent with patellazoles structure, thus
strongly supporting the assignment. The assembled genome was
considered to belong to an uncultured symbiont, designated as
Candidatus “Endolissoclinum faulkneri,” most closely related to
free-living marine α-proteobacteria.
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Pederin-led Discovery of the Onnamides
Pederin and mycalamides A and B, encoded by a mixed modular
PKS-non-ribosomal peptide synthetase (NRPS) system, are
highly active antitumor compounds (Narquizian and Kocienski,
2000). These compounds block mitosis at levels as low as
1 ng/ml by inhibiting protein and DNA synthesis without
aﬀecting RNA synthesis (Singh and Yousuf Ali, 2007). They
prevent cell division, and have been shown to extend the life
of cancerous mice. Consequently they have garnered interest
as potential anti-cancer treatments (Kanamitsu and Frank,
1987). These compounds were initially known exclusively from
terrestrial Paederus and Paederidus beetles and after many
years of speculation were ﬁnally shown to be produced by an
uncultured symbiotic Pseudomonas associated with the Paederus
fuscipes beetles using metagenomic approaches (Piel et al.,
2004a). Interestingly, these insects use pederin as a chemical
weapon against predators and when in contact with human
skin cause severe dermatitis (Borroni et al., 1991; Piel et al.,
2004a). Metabolites with high structural similarity to pederin
were identiﬁed in the marine sponges of the order Lithistida
(Bewley and Faulkner, 1998), many of which exhibit extremely
potent antitumor activity and also selectivity against solid
tumor cell lines (Cichewicz et al., 2004). A pederin-informed
survey of PKS amplicons from the Japanese sponge Theonella
swinhoeimetagenome, a species with exceptionally rich chemistry
(Fusetani and Matsunaga, 1993; Bewley and Faulkner, 1998),
revealed a wide range of distinct KS sequences (Piel et al.,
2004b). Three of these belonged to an evolutionarily distinct
enzyme family, the trans-acyl-transferase (trans-AT) PKSs, and
corresponded to onnamide biosynthesis pathways. These trans-
AT PKSs therefore were expected to encode the pederin-like
compounds with antitumor activity produced by the sponges.
Further, screening of the metagenomes from other T. swinhoei
specimens revealed that these trans-AT PKSs could only be
detected in the sponges which had previously shown to contain
pederin-type compounds, while no ampliﬁcation was obtained
for sponges devoid of these compounds. It has now been
conﬁrmed that the onnamides (Figure 2) are produced by an
unculturable symbiont, ‘Candidatus Entotheonella spp.’ (Wilson
et al., 2014).
Psymberin
Psymberin, a highly cytotoxic and selective antitumor polyketide,
has been isolated from a number of diﬀerent marine sponges
(Bielitza and Pietruszka, 2013). It took 11 years and 600 samples
for the structure of this compound to be assigned. There is
immense interest in this natural product due to its complex
architecture, biological properties and scarcity in nature. As with
FIGURE 2 | A representation of the ubiquity of “Entotheonella”
species in taxonomically diverse marine sponges and the notable
secondary metabolites they produce. Metabolite structure and function
information obtained directly from the Theonella swinhoei and Discodermia
calyz sponges informed a targeted metagenomic approach to identify the
biosynthetic pathways encoding these metabolites. This ultimately led to
the discovery of “Entotheonella,” described as “talented producers” due to
their chemically diverse metabolism. The full potential of Entotheonella
species has yet to be explored. Photos were provided by T. Mori, P.
Poppe, and T. Wakimoto.
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the onnamides, psymberin is a member of the pederin family,
also synthesized by a trans-AT PKS (Piel et al., 2004b), but
is distinguished from the other pederins due to its excellent
cytotoxicity values which exceeds those of the other family
members. A trans-AT PKS PCR screening approach, as described
above for the onnamides, was used to elucidate the complete
biosynthetic pathway for psymberin from the Psammocinia
aﬀ. bulbosa sponge metagenome (Fisch et al., 2009). The
genomic region showed typical bacterial architecture, suggesting
a bacterial symbiont origin. However, unlike for the pederin and
onnamide examples, there were not enough similarities to other
bacterial genes to identify the bacterium.
Polytheonamides
The polytheonamides (Figure 2) represent another group of
exceptionally potent natural product toxins isolated from the
Theonella swinhoei sponges, and are particularly noteworthy
for their size and structural complexity (Hamada et al., 2010).
These 48-residue peptides were expected to be products of
a non-ribosomal peptide synthetase, since of the 19 diﬀerent
amino acids that constitute these peptides, 13 are non-
proteinogenic. Furthermore, the peptides include multiple
D-conﬁgured and C-methylated residues. However, the size
of the NRP biosynthetic machinery required to produce
a 48 residue peptide prompted a search for an unusual
ribosomal pathway. With the knowledge of the peptide sequence,
degenerate PCR primers were designed to the proposed
precursor peptide, and used to conduct a semi-nested PCR
from a T. swinhoei metagenome (Freeman et al., 2012).
Sequenced amplicons revealed codon sequences that precisely
corresponded to an unprocessed polytheonamide precursor,
not only conﬁrming a ribosomal origin, but also suggesting
that it is produced by a bacterial endosymbiont. Further
screening of the metagenome library revealed the entire 12
gene biosynthetic pathway. Microscopic analysis of T. swinhoei
(Y chemotype) samples identiﬁed a highly enriched population
of ﬂuorescent ﬁlamentous bacteria showing morphological
similarity to the symbiont ‘Candidatus Entotheonella palauensis,’
the suspected producer of antifungal peptides isolated from a
Palauan T. swinhoei chemotype (Schmidt et al., 2000). Using
single cell genomics (ﬂuorescence assisted cell sorting and whole
genome ampliﬁcation) combined with pathway speciﬁc PCR, the
identiﬁcation of the polytheonamide producer was attributed
to an uncultured “Entotheonella” spp. (Wilson et al., 2014).
Further, screening using onnamide pathway speciﬁc markers
indicated that the “Entotheonella” spp. were the source of both
the onnamide and polytheonamide compounds.
Calyculin A
Calyculin A was originally described in 1986 as a major cytotoxic
compound isolated from Discodermia calyx, a marine sponge
of the Theonellidae family (Kato et al., 1986), and is to date
associated exclusively with marine sponges (Wakimoto et al.,
2014). Calyculin A represents a fairly sophisticated and unique
structure whose biosynthesis was reminiscent of a polyketide
and non-ribosomal peptide hybrid pathway incorporating
some remarkable modiﬁcation processes. Calyculin-related
compounds have been isolated from a number of diﬀerent
sponges which hinted toward a symbiont being responsible
for its production (Dumdei et al., 1997; Edrada et al., 2002;
Kehraus et al., 2002). However, it was only very recently that the
biosynthetic gene cluster was identiﬁed through a metagenomic
approach. Based on the initial hypothesis that calyculin A was
a type I polyketide, a metagenome library of D. calyx was
sequentially screened by PCR ampliﬁcation using trans-AT-
type KS, adenylation domain (NRPS) and HMGS-like motif
primers (Wakimoto et al., 2014). Spanning over 150 kb, a gene
cluster containing 29 KS and 5 A domains was identiﬁed. The
collinearity between the order of the modules and the order
of the biosynthetic reactions provided strong evidence that the
cluster encoded calyculin A synthesis. Using the entire gene
cluster as a probe and employing CARD-FISH, as well as laser
microdissection, a ﬁlamentous bacteriumwas identiﬁed to harbor
the calyculin pathway. The 16S rRNA sequence of this bacterium
displayed 97% identity to the ‘Candidatus Entotheonella factor’
isolated from the T. swinhoei sponges.
From Function to Genes to Species
The power of metagenomics to identify novel and
pharmaceutically relevant organisms, resulting from ﬁrst
obtaining functional and structural data, has been elegantly
represented in the examples discussed above. To demonstrate this
further, the “Entotheonella” and the ‘Candidatus Endolissoclinum
faulkneri’ stories are elaborated (Figure 2).
Genome sequencing of several of the single cell sorted
events in the Wilson et al. (2014) study indicated the presence
of two closely related “Entotheonella” variants, with 97.6%
identical 16S rRNA sequences, and 97% identity to E. palauensis.
These are only 82% identical to representatives from known
bacterial phyla and form a well-separated clade, and therefore
have been proposed to represent a new candidate phylum
“Tectomicrobia.” Both genomes exceed 9 Mb, representing some
of the largest known prokaryote genomes. Analysis of the
metabolic genes identiﬁed over 28 biosynthetic clusters, encoding
ribosomal, polyketide and non-ribosomal peptide biosynthesis.
Using bioinformatics based predictions, several of the clusters
could be assigned to known bioactive peptides isolated from
the Japanese T. swinhoei, and together with tandem mass
spectrometry-based molecular networking a high diversity of
previously unknown metabolite families were identiﬁed. The
combination of these properties is so rare that the new phylum
to which these isolates have been assigned is considered the
successor to the Actinobacteria, the well-known source of
the majority of the world’s antibiotics and anticancer agents
(Jaspars and Challis, 2014). Screening for the distribution of
these talented producers indicated that they are geographically
widespread and are symbiotically associated with other sponge
types (Wilson et al., 2014; Figure 2). The discovery of a calyculin
producing “Entotheonella” symbiotically associated with D. calyx
further expands the number of biosynthetic enzymes and
chemical scaﬀolds encompassed by this genus (Wakimoto et al.,
2014), but also serves to highlight the diﬀerences between the
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“Entotheonella” populations in diﬀerent sponges. Attempts to
culture the producing symbionts have been unsuccessful. Access
to the genome sequences should give important insights to the
organism’s metabolism, and such clues to their physiology could
inform on the development of appropriate culturing strategies.
Several uncultured symbionts have been successfully isolated
using such genome sequence-guided strategies (Renesto et al.,
2003; Bomar et al., 2011).
In the Kwan et al. (2012) study the patellazole encoding
Ca. E. faulkneri genome assembled to a mere 1.48 Mbp
and showed extensive genome reduction characteristics. Unlike
other bacteria with streamlined genomes, Ca. E. faulkneri has
distinguishing features which strongly suggest that it could not
exist independently of its host, L. patella. Phylogenetic analysis
of patellazole-containing and patellazole-negative tunicates
provides evidence that the symbiont has coevolved with the
tunicate host and would therefore be transmitted vertically. The
patellazole pathway is the only secondary metabolite pathway
encoded in the Ca. E. faulkneri genome, and represents >10%
of the coding sequence. The maintenance of such a large pathway
in a genome that is so streamlined as to eliminate most functions
indicates its importance to the symbiotic relationship. However,
the patellazoles are highly toxic to eukaryotic cells and are found
in high amounts in L. patella, and it is intriguing that the host
has apparently adapted to tolerate such high concentrations.
Clearly the patellazoles provide important chemical defense to
the host which in turn ensures that the symbiont is maintained.
Interestingly, Ca. E. faulkneri is found sporadically in L. patella
tunicates. Patellazole-positive and negative L. patella collected
within 250 m of each other show that Ca. E. faulkneri is
only associated with the patellazole-positive colonies, and only
in the zooids fraction. This is despite patellazole-positive and
negative colonies having nearly identical tunicate phylogeny, and
containing virtually identical microbial communities, with the
exception of the Ca. E. faulkneri. The exclusive localization of Ca.
E. faulkneri in the zooids and only in certain L. patella colonies
is intriguing. Considering the L. patella zooids ﬁlter feed and
excrete waste into the cloacal cavities, this could perhaps provide
some leads of investigation to further understanding the Ca. E.
faulkneri localization and the symbiotic relationship.
These discoveries raise several fundamental biological
questions relating to: symbiont and secondary metabolite
evolution, mechanisms of natural product symbiosis, the role of
the natural products in imparting a direct competitive advantage
to individual members of a bacterial consortium, and how
these symbiotic interactions contribute to the ecology of the
marine environment. However, what is now clearly appreciated
is that the genomes of previously uncultured bacteria harbor an
unprecedented richness of novel compound diversity, and await
discovery.
Conclusion and Future Prospects
The remarkable exploration of marine organisms and their
structurally diverse natural products spans a highly active
period of over 40 years (Gerwick and Moore, 2012). With
attention turning to marine microorganisms as a source
of new natural product chemistry, and the realization that
many compounds previously isolated are metabolic products
of unculturable microbes, marine metagenomics promises to
illuminate new bioactivities and chemistries that were previously
unattainable. Despite metagenomics being a relatively young
technology, it is globally appreciated that major advances
are needed given the challenges that now bottleneck future
developments, irrespective of whether functional or sequence
guided approaches are to be employed. In order to maximize
our ability to harvest marine resources the synergic combination
of a number of complementary methodologies and integration
of functional and informatics approaches will be required (Reen
et al., 2015). The examples presented, employing a targeted
and function-guided strategy, demonstrate how metagenomic
technologies have advanced several research disciplines and our
understanding of microbial genetic and biological diversity and
ecology. Armed with information of the chemical structure and
biological activity of pharmaceutically relevant compounds, an
informed metagenomic strategy, in combination with in situ
hybridization, single cell-sorting, whole genome ampliﬁcation,
and next generation sequencing, has successfully identiﬁed
novel biosynthetic gene clusters and novel microbes that
produce the metabolites. The path that led from similar
compounds being found in organisms as divergent as marine
sponges and beetles, to the discovery that microorganisms were
the producers, and the role metagenomics played, makes a
fascinating story demonstrating a perfect blend of fundamental
and applied science, exemplifying the power of employing
integrated technologies.
For marine metagenomics to signiﬁcantly contribute to
delivering pharmaceutically relevant compounds, improvements
in, and integration of, various approaches and strategies is
key. One of the most important hindrances encountered
thus far in natural product research is re-isolation of known
compounds. Thus chemical and biological de-replication is a
crucial step in the process, and applies to metagenomic guided
discovery as well, irrespective of the metagenomic approach
employed. While sequence-based metagenomic approaches oﬀer
the power of discrimination, the expression of the pathways
and the functional and biochemical characterization of the
encoded products is crucial. Genome data is being produced
at a dizzying pace; however, without focusing on heterologous
expression challenges and the development of functional screens
our capacity to uncover and develop the next generation of
pharmaceutically relevant molecules will be limited (Reen et al.,
2015). There are two long standing schools of thought on
natural products discovery: ‘isolate and then test’ vs. ‘test and
then isolate’ (Gerwick and Moore, 2012). A parallel can be
drawn to employing metagenomic tools to natural product
discovery: “sequence and then test” vs. “test and then sequence.”
This review summarizes some of the most recent marine
discoveries through the latter approach, born out of traditional
chemistry-guided discovery conducted over several decades.
However, to maximize our capacity to mine metagenomes for
activities which have yet to be identiﬁed, parallel developments
in a number of technologies need continuous attention;
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including biological assay screening; isolation and separation
methods and analytical chemistry techniques. Peptidogenomics
represents a recent advancement in high throughput mass
spectrometry (MS; Kersten et al., 2011; Bouslimani et al., 2014;
Medema et al., 2014). This automated approach iteratively
matches the chemotypes of peptide natural products to their
biosynthetic gene clusters through de novo tandem MS (MSn)
and genome-mining (Reen et al., 2015). This constitutes a
paradigm shift from the one molecule-per-study approach to
drug discovery (Medema et al., 2014), and may be the key to
revealing novel marine natural products from metagenomes,
for advancement into the drug discovery development pipeline.
There is no doubt that as yet uncultured bacteria are a rich source
of novel bioactive molecules with potent therapeutic activity, and
these are exciting times to be a researcher in the ﬁeld.
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